

Pathway	Treatment of Axillary Hyperhidrosis.
Commissioned	<p>Botox treatment for axillary hyperhidrosis will only be funded when ALL of the following criteria apply:</p> <ol style="list-style-type: none"> 1. Generalised hyperhidrosis has been excluded; 2. Secondary focal hyperhidrosis has been excluded; 3. Excessive sweating occurs on a daily basis irrespective of ambient temperature; 4. Bathing and changes of clothing are required at intervals throughout the day; 5. The condition has a significant social or occupational impact; 6. A month's trial of daily topical therapy with Aluminium Chloride 20%, was either not tolerated, or failed to reduce the severity of symptoms to a tolerable level, which only sometimes interferes with daily activities.
Not Funded	<ul style="list-style-type: none"> • Surgical treatment of axillary hyperhidrosis is not funded. • Botox treatment for hyperhidrosis of the hands and feet is not funded. These patients can be referred to a dermatologist for a trial of iontophoresis.
Notes	Further treatments with Botox will only be funded if the last course produced a demonstrable reduction in sweating and the benefit lasted for at least 6 months.
Rationale	<ul style="list-style-type: none"> ▪ Policy based on <i>East midlands commissioning policy for cosmetic procedures 2014 Version 2.0</i> ▪ Surgical treatment, including sympathetic nerve denervation, carries the risk of significant complications including a compensatory increase in the production of sweat in another area of the body. ▪ For further information on the assessment of hyperhidrosis see http://cks.nice.org.uk/hyperhidrosis
Cohort	Adults.
Equality	Compliant with the Equality Act 2010.
Status	RED as defined in the Prior Approval Scheme Policy.
OPCS codes	

All codes required	
Localized hyperhidrosis	R61.0
Injection of therapeutic substance into skin	S53.2
Torsion dystonias and other involuntary movements drugs Band 1	X85.1
Skin of axilla	Z49.2
Version History	
No material changes from previous version.	
Authorised	
April 2019	
Review	
April 2024 Earlier if new evidence published by NICE or other authoritative body.	